As of December 8, 2017
If you would like additional information regarding a clinical trial, please contact us at:
If you believe your pet is eligible for a specific study, we recommend that you contact your veterinarian and request a referral. However, a referral may not be required to participate in some clinical trials.
Canine Aggression Study in Labrador Retriever, Beagle and Standard Poodle
- Description: This study is to compare genetic and behavior information between human directed aggressive dogs and non-aggressive (to both humans and animals) dogs in three different breeds to see if potential genetic and/or biomarkers may be identified.
- Eligibility: Pure bred Labrador Retrievers, Beagles, or Standard Poodles that are either affected dogs (human aggressive dogs) or control dogs (no aggression toward humans or animals) are eligible.
- Financial Incentive: No cost for collection of samples (blood). Blood collection can also be performed at the primary veterinarian office and shipped to us (cost for blood collection and shipping will be covered).
- Primary Investigator: Dr. Niwako Ogata
Behavioral and Physiological Responses in Dogs Under Social Anxiety
- Description: A study to compare behavioral and physiological responses to identify the dogs at risk of social anxiety (both home and an exam room environment).
- Eligibility: Clinically healthy dogs that must be neturered/spayed and between the ages of 1-13 years old can participate in the study.
- Financial Incentive: No cost for collection of samples (saliva).
- Primary Investigator: Dr. Niwako Ogata
Atopic Dermatitis in Dogs
- Description: The purpose of this study is to investigate the structure of the skin in dogs with atopic dermatitis. Skin biopsies and blood from dogs with atopic dermatitis and controls will be analyzed (immunofluorescence, RNA isolation, lipids and protein isolation). A better understanding of the disease may lead to new and improved treatments.
- Eligibility: Any dog with clinically confirmed atopic dermatitis or a non-AD skin condition. Dogs must not have been treated with immunosuppressive or anti-inflammatory medication for at least two weeks.
- Financial Incentive: There is no compensation for participation in this study; however, the biopsy and blood work are performed at no cost to you.
- Primary Investigator: Dr. Paulo Gomes
MRI for Dogs Suspected to Have Brain Tumors
- Description: A study to develop MRI in the diagnosis of dogs with brain tumors.
- Eligibility: Any dog that is suspected to be suffering from a brain tumor. Examination by the Neurology & Neurosurgery service must confirm the suspicion of a brain tumor and eligibility for the study. Blood work and chest radiographs (from within the last month) must have already been performed – these may be performed at the referring veterinarian office before the appointment at Purdue.
- Financial Incentive: The cost of the MRI is significantly reduced.
- Primary Investigator: Dr. Timothy Bentley
Surgery for Dogs with Suspect Brain Tumor
- Description: The purpose of this study is to collect brain tumors for future investigation of issues like what mutations cause brain tumors, how brain tumors grow or whether they cause any abnormalities in the blood or urine.
- Preliminarily diagnosed with a brain tumor
- MRI, Chest Radiographs and blood work already completed
- Forward the MRI to Dr. Bentley to determine eligibility
- Tests may be performed at Purdue but paid by owner
- Tumor is operable
- Owner consent to remove a lymph node at time of surgery
- Financial Incentive: The owner pays the first $500 and the funding agency will cover the remaining surgery cost – including anesthesia, histology, and post-operative care. Pet owner is required to pay all other expenses incurred in the Purdue University Veterinary Teaching Hospital (PUVTH). Chemotherapy, radiation, vaccines or any expenses not related to the surgery must be paid by the pet owner.
- Primary Investigator: Dr. Tim Bentley
Vemurafenib Treatment in Dogs with Bladder Cancer, i.e. Transitional Cell Carcinoma (TCC)
- Description: The purpose of this study is to determine the anti-tumor effects, the toxicity (or lack thereof), and the appropriate dose of Vemurafenib in dogs with TCC. Vemurafenib is a drug that kills tumor cells that have a very precise mutation. The goal is to improve the outlook for pet dogs and people with cancer.
- Biopsy proof of TCC
- Confirmed BRAF V600E mutation in TCC cells in the urine (a urine test)
- Measurable cancer lesions that can be followed to assess antitumor effects
- Acceptable “performance status” (the dogs still feels OK)
- Expected survival ≥ 6 weeks
- Acceptable kidney function (serum creatinine ≤ 2mg/dl)
- Financial Incentive: The pet owner is required to pay $250.00 per month for the expenses incurred in the Purdue University Veterinary Teaching Hospital (PUVTH) related to the treatment and monitoring. The funding agency will cover the remainder of the cost related to the Vemurafenib treatment and monitoring in the PUVTH. Any work done outside of the PUVTH or any expenses not related to the Vemurafenib treatment must be paid by the pet owner.
- Primary Investigator: Dr. Deborah Knapp
Golden Retriever Pigmentary Uveitis (PU)
- Description: A study to better understand the disease progression of PU and establish a DNA bank of samples from both affected and normal Golden Retrievers.
- Eligibility: Any purebred Golden Retriever.
- Financial Incentive: There is no compensation for participation in this study. However, the ocular examination is performed at no cost to you.
- Primary Investigator: Dr. Wendy Townsend
Polyarthritis – Folate-receptor Targeted Drug Delivery
- Description: A study to evaluate a new folate-receptor drug complex for the treatment of immune mediated polyarthritis in dogs. The drug has strong anti-inflammatory activity, similar to the new rheumatoid arthritis drugs for humans.
- Eligibility: Dogs with naturally occurring immune mediated polyarthritis.
- Financial Incentive: All costs related to the diagnosis and rechecks through the 16 week recheck will be reimbursed to the owner. The owner is responsible for the cost of the initial visit for diagnosis. During this visit, the scintigraphy will be done free of charge. Once the diagnosis of immune mediated polyarthritis is made, the owner will be advised about eligibility for enrollment.
- Primary Investigator: Dr. Gert Breur
This article has been originally published in Purdue University.